-
Je něco špatně v tomto záznamu ?
Ph- myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide
M. Košťál, J. Schwarz, P. Ovesná, M. Penka, P. Dulíček, for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
Grantová podpora
MH CZ - DRO (UHHK, 00179906) and PROGRES Q40/08
Ministerstvo Zdravotnictví Ceské Republiky
NLK
ProQuest Central
od 1998-06-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2011-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1998-06-01 do Před 1 rokem
- MeSH
- cévní mozková příhoda etiologie MeSH
- chinazoliny terapeutické užití MeSH
- dospělí MeSH
- fibrinolytika terapeutické užití MeSH
- Janus kinasa 2 genetika MeSH
- lidé středního věku MeSH
- lidé MeSH
- myeloproliferativní poruchy komplikace genetika MeSH
- rizikové faktory MeSH
- senioři MeSH
- trombóza etiologie prevence a kontrola MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Arterial thrombosis is a common complication in patients with Ph- myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n = 168) or Transient Ischemic Attack (TIA) (n = 140), and in 1,193 MPN control subjects (without clinical history of thrombosis). These patients were registered in a prospective manner, providing a follow-up period after Anagrelide treatment. The median age of the patients in the experimental group was of 56 years of age (ranging from 34-76) and of 53 years of age (ranging from 26-74) in the control group (p < 0.001). Using a multivariate model, we determined the following as risk factors: JAK2V617F mutation (OR 2.106, 1.458-3.043, p = 0.006), age (OR 1.017/year, 1.005-1,029, p = 0.006), male gender (OR 1.419, 1.057-1.903, p = 0.020), MPN diagnosis (OR for PMF 0.649, 0.446-0.944, p = 0.024), BMI (OR 0.687 for BMI > 25, 0.473-0.999, p = 0.05) and high TAG levels (OR 1.734, 1.162-2.586, p = 0.008), all of which were statistically significant for CMP development. Concerning the risk factors for thrombophilia, only the antiphospholipid syndrome (OR 1.994, 1.017-3.91, p = 0.048) was noteworthy in a stroke-relevant context. There was no significant difference between the blood count of the patients prior to a stroke event and the control group, both of which were under a cytoreductive treatment. We found that age, male gender, JAK2V617F mutation, previous venous thrombosis, and hypertriglyceridemia represent independent risk factors for the occurrence of a stroke in Ph- MPN patients.
Department of Clinical Hematology Faculty Hospital Brno Masaryk University Brno Czech Republic
Faculty of Medicine Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic
Institute of Hematology and Blood Transfusion Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004729
- 003
- CZ-PrNML
- 005
- 20220127145032.0
- 007
- ta
- 008
- 220113s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11239-020-02175-8 $2 doi
- 035 __
- $a (PubMed)32578055
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Košťál, Milan $u University Hospital Hradec Králové, Charles University, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic. kosmil@seznam.cz
- 245 10
- $a Ph- myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide / $c M. Košťál, J. Schwarz, P. Ovesná, M. Penka, P. Dulíček, for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms
- 520 9_
- $a Arterial thrombosis is a common complication in patients with Ph- myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n = 168) or Transient Ischemic Attack (TIA) (n = 140), and in 1,193 MPN control subjects (without clinical history of thrombosis). These patients were registered in a prospective manner, providing a follow-up period after Anagrelide treatment. The median age of the patients in the experimental group was of 56 years of age (ranging from 34-76) and of 53 years of age (ranging from 26-74) in the control group (p < 0.001). Using a multivariate model, we determined the following as risk factors: JAK2V617F mutation (OR 2.106, 1.458-3.043, p = 0.006), age (OR 1.017/year, 1.005-1,029, p = 0.006), male gender (OR 1.419, 1.057-1.903, p = 0.020), MPN diagnosis (OR for PMF 0.649, 0.446-0.944, p = 0.024), BMI (OR 0.687 for BMI > 25, 0.473-0.999, p = 0.05) and high TAG levels (OR 1.734, 1.162-2.586, p = 0.008), all of which were statistically significant for CMP development. Concerning the risk factors for thrombophilia, only the antiphospholipid syndrome (OR 1.994, 1.017-3.91, p = 0.048) was noteworthy in a stroke-relevant context. There was no significant difference between the blood count of the patients prior to a stroke event and the control group, both of which were under a cytoreductive treatment. We found that age, male gender, JAK2V617F mutation, previous venous thrombosis, and hypertriglyceridemia represent independent risk factors for the occurrence of a stroke in Ph- MPN patients.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fibrinolytika $x terapeutické užití $7 D005343
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Janus kinasa 2 $x genetika $7 D053614
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a myeloproliferativní poruchy $x komplikace $x genetika $7 D009196
- 650 _2
- $a chinazoliny $x terapeutické užití $7 D011799
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a cévní mozková příhoda $x etiologie $7 D020521
- 650 _2
- $a trombóza $x etiologie $x prevence a kontrola $7 D013927
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Schwarz, Jiří $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $u 1st Medical Faculty, Institute of Clinical and Experimental Hematology, Charles University, Prague, Czech Republic
- 700 1_
- $a Ovesná, Petra $u Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Penka, Miroslav $u Department of Clinical Hematology, Faculty Hospital Brno, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Dulíček, Petr $u University Hospital Hradec Králové, Charles University, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic
- 710 2_
- $a for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms
- 773 0_
- $w MED00007760 $t Journal of thrombosis and thrombolysis $x 1573-742X $g Roč. 51, č. 1 (2021), s. 112-119
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32578055 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145029 $b ABA008
- 999 __
- $a ok $b bmc $g 1752032 $s 1155878
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 51 $c 1 $d 112-119 $e - $i 1573-742X $m Journal of thrombosis and thrombolysis $n J Thromb Thrombolysis $x MED00007760
- GRA __
- $a MH CZ - DRO (UHHK, 00179906) and PROGRES Q40/08 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20220113
